An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Lenvatinib is a drug used to treat differentiated thyroid cancer. It works by inhibiting the growth of the blood vessels that tumors need to grow and spread. It is taken orally (by mouth).
Anaplastic thyroid cancer is a rare and aggressive cancer that has a tendency to metastasize (spread elsewhere in the body). There is no standard therapy for this disease. In this study, researchers are evaluating the safety and effectiveness of lenvatinib to treat patients with anaplastic thyroid cancer. All patients in this study will receive lenvatinib.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have anaplastic thyroid cancer.
- Prior chemotherapy is permitted. Patients must recover from the serious side effects of previous treatments before entering the study.
- Newly diagnosed patients who can be treated with a combination of different therapies (such as surgery, chemotherapy, and/or radiation therapy) may not participate in this study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Eric Sherman at 646-888-4234.